Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast.

The event will be hosted at the “SECOND Floor” venue located at 849 6th Ave, New York, NY 10001. The event will begin at 7:30 a.m. ET with breakfast, followed by formal presentations starting at 8:00 a.m. ET, with the webcast portion of the event concluding by approximately 12:00 p.m. ET.

During the event, Evolus’ management team will provide in-depth presentations and discussions of the Company’s strategic vision, investment strategies, growth levers, and financial outlook. The formal presentations will be followed by a Q&A session.

The Investor Day is open to the investment community and pre-registration is required. To pre-register for the event, please visit the registration page of the Evolus Investor Day website here. Confirmation and additional event details will be provided to registered attendees. The live webcast of the event will also be available on the Evolus Investor Day website.

Following the event, a replay of the webcast and supporting materials will be made available on the Investor Relations page of the Evolus website here.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese Aesthetics S.A.S.

Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com

Media: Email: media@evolus.com

Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Evolus Charts.
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Evolus Charts.